- €48.78bn
- €44.92bn
- $4.15bn
Brief: Argenx SE Q3 NET INCOME USD 344.258 MILLION
Refile: BUZZ-'Overall a relief': TrumpRx price cuts deals boost European pharma stocks
Top of the Street: Telenor, Telia, Novartis, Argenx, Puma
Deutsche Bank cuts Argenx to 'hold' on valuation
Europe Research Roundup: Energean, Playtech, Vistry Group
Europe Research Roundup: Alfen, Argenx, JDE Peet's
RBC initiates argenx with 'outperform' on strong belief in Vyvgart
Brief: ArgenX Shows Positive Vyvgart Results In Adapt Seron Study
Europe Research Roundup: BAE Systems, ITM Power, Lloyds
Argenx tops STOXX on strong gMG drug Vyvgart sales momentum
Brief: Argenx Q2 Net Income USD 245.358 Million
Top of the Street: Handelsbanken, Arkema, Zealand Pharma, SOBI, Argenx
DB expects EU pharma 'malaise' to continue amid US headwinds
Brief: ArgenX Advances Clinical Development Of ARGX-119
ArgenX rises after European Commission approves immune disorder drug
Brief: Argenx Announces European Commission Approval Of Vyvgart Subcutaneous Injection
Europe Research Roundup: Barclays, Carlsberg, Sodexo
Brief: Argenx Presents New Data Highlighting Phase 2 Results In Myositis And Sjogren’S Disease
Europe Research Roundup: AB Dynamics, DHL Group, Gerresheimer